D. E. Shaw & Co., Inc. Coherus Bio Sciences, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.59 - $3.85 $920,288 - $2.23 Million	-578,798 Reduced 81.94%	127,610 $424,000
Q3 2023 Nov 14, 2023	SELL	$3.74 - $5.45 $1.61 Million - $2.35 Million	-430,740 Reduced 37.88%	706,408 $2.64 Million
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $525,938 - $1.15 Million	138,770 Added 13.9%	1,137,148 $4.86 Million
Q1 2023 May 15, 2023	BUY	$5.89 - $10.52 $1.64 Million - $2.93 Million	278,552 Added 38.7%	998,378 $6.83 Million
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $707,164 - $1.25 Million	124,282 Added 20.87%	719,826 $5.7 Million
Q3 2022 Nov 14, 2022	BUY	$7.17 - $13.87 $350,462 - $677,951	48,879 Added 8.94%	595,544 $5.72 Million
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $1.06 Million - $2.39 Million	180,878 Added 49.45%	546,665 $3.96 Million
Q1 2022 May 16, 2022	BUY	$10.92 - $16.41 $2.95 Million - $4.43 Million	270,122 Added 282.36%	365,787 $4.72 Million
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $806,278 - $968,452	50,998 Added 114.17%	95,665 $1.53 Million
Q3 2021 Nov 15, 2021	SELL	$12.68 - $17.79 $636,472 - $892,969	-50,195 Reduced 52.91%	44,667 $718,000
Q2 2021 Aug 16, 2021	SELL	$12.95 - $15.41 $2.26 Million - $2.69 Million	-174,771 Reduced 64.82%	94,862 $1.31 Million
Q1 2021 May 17, 2021	SELL	$14.42 - $21.39 $200,971 - $298,112	-13,937 Reduced 4.91%	269,633 $3.94 Million
Q4 2020 Feb 16, 2021	SELL	$16.56 - $18.94 $5.02 Million - $5.74 Million	-303,064 Reduced 51.66%	283,570 $4.93 Million
Q3 2020 Nov 16, 2020	SELL	$17.41 - $19.89 $4.42 Million - $5.05 Million	-253,885 Reduced 30.21%	586,634 $10.8 Million
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $8.68 Million - $11.5 Million	-601,624 Reduced 41.72%	840,519 $15 Million
Q1 2020 May 15, 2020	BUY	$11.67 - $22.53 $3.94 Million - $7.61 Million	337,631 Added 30.57%	1,442,143 $23.4 Million
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $11.9 Million - $15.5 Million	726,647 Added 192.3%	1,104,512 $19.9 Million
Q3 2019 Nov 14, 2019	BUY	$16.3 - $23.37 $2.02 Million - $2.9 Million	124,142 Added 48.93%	377,865 $7.66 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $688,418 - $1.16 Million	-52,551 Reduced 17.16%	253,723 $5.61 Million
Q1 2019 May 15, 2019	SELL	$8.38 - $15.5 $602,513 - $1.11 Million	-71,899 Reduced 19.01%	306,274 $4.18 Million
Q4 2018 Feb 14, 2019	BUY	$8.65 - $16.28 $794,485 - $1.5 Million	91,848 Added 32.08%	378,173 $3.42 Million
Q3 2018 Nov 14, 2018	BUY	$14.45 - $20.25 $2.56 Million - $3.59 Million	177,142 Added 162.24%	286,325 $4.72 Million
Q2 2018 Aug 14, 2018	BUY	$10.25 - $17.45 $963,930 - $1.64 Million	94,042 Added 621.11%	109,183 $1.53 Million
Q1 2018 May 15, 2018	SELL	$9.1 - $13.7 $208,981 - $314,620	-22,965 Reduced 60.27%	15,141 $167,000
Q4 2017 Feb 14, 2018	SELL	$8.35 - $14.4 $575,440 - $992,376	-68,915 Reduced 64.39%	38,106 $336,000
Q3 2017 Nov 14, 2017	BUY	$11.1 - $14.5 $1.19 Million - $1.55 Million	107,021	107,021 $1.43 Million

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

77.9M

Call Options Held

40.7K

Put Options Held

50.1K

Black Rock Inc. New York, NY

11.8M
Shares

$18.5 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

11.3M
Shares

$17.8 Million
0.0% of portfolio
Rubric Capital Management LP New York, NY

10.4M
Shares

$16.3 Million
0.3% of portfolio
Kohlberg Kravis Roberts & Co. L.P. New York, NY

3.04M
Shares

$4.77 Million
0.18% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

2.86M
Shares

$4.49 Million
0.0% of portfolio

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account